

**Online-Only Supplemental Material****Supplemental Table S1.** Principal Investigators for the TIGRIS Registry

<i>Country</i>	<i>Principal Investigators for the TIGRIS Registry</i>
<i>Belgium</i>	M. Vrolix, C. Van Mieghem, M. Detollenaere, F. Cools, B. Vankelecom, D. Faes, S. Gevaert, P. Dejaegher
<i>Denmark</i>	H. Rickers, J. Skov Jensen, L. Holmvang, H. Nielsen, T. Bjerregaard Larsen, J. Brønnum-Schou, E. Vibeke Friis
<i>Finland</i>	J. Airaksinen, S. Vikman, J. Niva, A. Hadjиков
<i>France</i>	E. Ferrari, G. Range, G. Jean-Louis, O. Dubreuil, A. Ohanessian, T. Cuisset, P. Goube
<i>Germany</i>	P. Schwimmbeck, T. Schäufele, A. Joost, S. Lüders, E. Giannitsis, J. Brachmann, U. Zeymer, J. vom Dahl, R. Prondzinsky, O. Bruder, D. Westermann, T. Gori, F. Stahl, V. Rudolph, J. Weil, V. Wiechern, S. Behrens, B. Subin, D. Leistner, R. Gaub, S. Schellong, E. Schmidt, S. Markovic, H. Ebel, J. Bott, C. Kadel, K. Kleinertz, H. Mudra, H. Darius, S. Achenbach, C. Contzen, J. Stöbel, O. Maus, A. Rinke, C. Bickel
<i>Italy</i>	C. Cavallini, Z. Olivari, R. Mazzucco, G. Marenzi, S. Berti, P. Perrone Filardi, F. Pestelli, S. Novo, C. Rapezzi, C. Condorelli, G. Casolo, P. Franco Terrosu, C. Mauro
<i>Netherlands</i>	M.L.W.M. Wetering van de, F.F. Willems, G. Hoedemaker, B.J. Berg van den, E. Ronner, M.J.W. Götte, J.C.M. Hal van, Dr. Schellings, F.R. Hartog den, G.L. Bartels, J.F. Küpper, H.P. Beijerbacht, T. Lenderink, A.F.M. Kuijper, M.E.R.M. Daele van, N.Y.Y. Al-Windy, S.H.K. The
<i>Norway</i>	D. Nilsen, E. H. Øie, R.A.M. De Boer
<i>Portugal</i>	C. Gavina, L. Alves, P. Santos, J. Ferreira Santos, F. Matias, D.Ferreira, J. Mimoso, R. Lima, A. Gaspar
<i>Romania</i>	G. Stanciulescu, D. Darabantiu, D. Zdrengha, N. Trocan, M. Dorobantu, M. C. Tomescu, S. Huidu, R. Musetescu, C. Bengus, M. Bogdan, S. Balanescu, L. Protopopescu, I. Manitiu, M. Vladioianu, L. Petrescu
<i>Spain</i>	J. Nevado Portero, G. Arquero, J. Sadurní Serrasolsas, J.A. Barrabes Riu, D. Pilar Mazon Ramos, V. I. Arrarte Esteban, A. Fernandez Ortiz, P. Pavia, J. Bruguera Cortada, A. Cequier Filiat, J.L. Blanco Coronado, F.J. Fernandez Portales, M. San Martín, R. Martín Asenjo, F. Marín Ortuño, M. Piqué, A. García Lledó, T. Ripoll, J.G. Sánchez Ramos

<i>Turkey</i>	E. Bozkurt, M. Bostan, E. Yeter, A. Çamsarı, R. Altındağ, İ. Keleş, E. Atalar, C. Ceyhan
<i>United Kingdom</i>	A. Moriarty, R. Storey, B. O'Rourke, A. Pell, M.J. Dayer, R. Sharma, S. Hoole, A. Bakhai, J. Cotton
<i>Australia</i>	D. Brieger, N. Collins, M. Sader, C. Hammett, A. Lee, G. Nelson, P. Garrahy, P. Thompson, R. Jayasinghe, D. Eccleston, W. van Gaal, A. Whelan, J. French, J. Waites, R. Dick, K. Greaves
<i>China</i>	M. Genshan, X. Longgen, S. Guohai, C. Jiyan, G. Junbo, L. Bao, Y. Zhuhua, T. Guizhou, Q. Shubin, H. Yong, L. Han, J. Yan, Z. Yang, W. Yanni, Z. Zheng, C. Hongliang, Y. Lixia, Y. Zhenyu, Y. Jinchuan
<i>India</i>	R. Sivakumar, J.P. Sawhney, U. Kaul, V. Mehta, A. Abhyankar, R. Gupta, T. Nair, P.P. Mohanan, D. Kahali, H.K. Bali, P. Arora, M.S. Hirematth, A. Mullasari, P.C. Rath
<i>Japan</i>	Y. Morino, H. Niinuma, K. Nakao, T. Himi, S. Hokimoto, Y. Ozaki, T. Miura, S. Kitaguchi, K. Saku, J. Ako, W. Shimizu, K. Kawai, Y. Kobayashi, S. Mizuno, Y. Kazatani, K. Miwa, H. Shimokawa, N. Maejima, Y. Minoru, R. Kawaguchi, Y. Tomoguchi, T. Onodera, S. Hosokawa, T. Noguchi, S. Suwa, T. Matsumoto, T. Miyamoto, Y. Nakagawa, A. Wada, Y. Ikari, T. Ueno, K. Nishioka
<i>South Korea</i>	J. Yoon, K.S. Cha, T.-J. Cha, J.-K. Chae, C.-W. Nam, S.W. Kim, D.-I. Kim, S.M. Kim, M.-H. Jeong, J.S. Koh, J.-H. Lee, S.W. Choi
<i>Argentina</i>	J.L.C.N. Estrada, E.A. Duronto, R.B.S. Zarandon, E.A. Falu, M.S. Trivi, S.M. Macin, C.A. Rapallo, A.D. Hrabar, H.E. Fernandez, S.M. Muryan, D.J. Anauch, D.L. Paolantonio, O.A. Salomone
<i>Brazil</i>	A.P.M. Kormann, D.G. da Silva, Junior, J.C.F. Braga, L.N. Maia
<i>Canada</i>	C. Constance, S. Vize, A. Glanz, A. Lamy, M. Gupta, Y. Pesant, W. Cantor, R. Petrella, R. Bessoudo (Marr), A.S. Pandey, A. Bell, I. Teitelbaum, R. Chehayeb, R. Dupuis
<i>Colombia</i>	C. Arana, M. Herrera, D.I. Molina, M. Urina, N. Jaramillo, R. Fernandez, B. Vesga, H. Duque, J.L. Accini, F. Manzur, C. Jaramillo
<i>Mexico</i>	E.D. y Díaz, A.B. Ruiz, G.R. Martínez, I.R. Briones, F.P. Padilla, J.C.P. Alva, O.F. Fierro
<i>USA</i>	J.J. Kmetzo, N. Mayer, N. Singh, R. Sangrigoli, W. Bennett, D. Schneider, E. Claxton, M. Newell, N.K. Mann, P. Gordon, E. Korban, R. Mehta, M. McKenzie, K. Friedman, W.J. French, T. Wang, W. Sheldon, J.K. Amin, M. Baig, T. Haddad, A. Wiseman, B. Herbstman, H. Taheri, L. Blacher, G. Stouffer, K. Tummalapalli, J. Ghitelman, A. Schwarcz, R. D'Agostino, R. Davidson, J. Duffy (Tonkon), E. Kaluski, J. Petersen II, M. Ball, W. Batchelor
<i>Venezuela</i>	N. Antepara, S. Tovar, L. Fariña, C. Delgado, Á. Avendaño

**Supplemental table S2.** Baseline characteristics by history of atrial fibrillation before enrolment

Variable	No history of AF (N=7575)	History of AF (N=702)	p value
<b>Demographics &amp; clinical variables</b>			
Female	1812 (23.9)	179 (25.5)	0.35
Age (years)	66.7 (8.6)	71.3 (7.9)	<0.001
BMI (kg/m <sup>2</sup> )	27.5 (4.7)	27.8 (4.6)	0.13
SBP (mmHg)	131.6 (17.7)	132.7 (19.2)	0.10
Heart rate (bpm)	68.2 (10.8)	68.3 (11.7)	0.76
Smoking status			<0.001
Never	2821 (37.2)	286 (40.8)	
Former	3704 (48.9)	360 (51.4)	
Current	1049 (13.9)	55 (7.8)	
Living alone	1062 (14.2)	126 (18.0)	0.006
Region			<0.001
Europe	3720 (49.1)	406 (57.8)	
Asia & Australia	1942 (25.6)	123 (17.5)	
Latin America	1059 (14.0)	45 (6.4)	
North America	854 (11.3)	128 (18.2)	
<b>Comorbidities &amp; medical history</b>			
Diabetes mellitus			0.13
No diabetes	5039 (67.0)	459 (65.7)	
Non-insulin-treated	1780 (23.7)	156 (22.3)	
Insulin-treated	703 (9.3)	84 (12.0)	
Second prior MI	772 (10.2)	105 (15.0)	<0.001
Chronic kidney disease	563 (7.4)	110 (15.7)	<0.001
Major bleeding	189 (2.5)	58 (8.3)	<0.001
Peripheral arterial disease	493 (6.5)	88 (12.5)	<0.001
Congestive heart failure	787 (10.4)	204 (29.1)	<0.001
Angina	763 (10.1)	90 (12.8)	0.02
Valve replacement/repair	60 (0.8)	39 (5.6)	<0.001
Stroke or transient ischaemic attack	399 (5.3)	107 (15.2)	<0.001
Cancer	522 (6.9)	84 (12.0)	<0.001
COPD	521 (6.9)	89 (12.7)	<0.001
CV event requiring hospital stay in the past 6 months	333 (4.4)	77 (11.0)	<0.001
Bleeding event requiring hospital stay in the past 6 months	45 (0.6)	15 (2.1)	<0.001
Cardiac surgery in the past 6 months	32 (0.4)	10 (1.4)	<0.001
Visit to the cardiologist in the past 6 months	2407 (31.8)	269 (38.3)	<0.001
ED visit in the past 6 months for bleeding or CV disease	415 (5.5)	88 (12.5)	<0.001
GP visit in the past 6 months for bleeding or CV disease	1526 (20.1)	169 (24.1)	0.01
<b>Medications at enrolment</b>			
Oral anticoagulation	233 (3.1)	348 (49.6)	<0.001

Variable	No history of AF (N=7575)	History of AF (N=702)	p value
No antiplatelet therapy	90 (1.2)	171 (24.4)	0.03
Single antiplatelet therapy	118 (1.6)	153 (21.8)	
Dual antiplatelet therapy	25 (0.3)	24 (3.4)	
No oral anticoagulation	7342 (96.9)	354 (50.4)	<0.001
No antiplatelet therapy	153 (2.0)	23 (3.3)	
Single antiplatelet therapy	5208 (68.8)	249 (35.5)	
Dual antiplatelet therapy	1969 (26.0)	82 (11.6)	
ACEi or ARB	5774 (76.9)	522 (74.9)	0.24
Beta blockers	6057 (80.6)	587 (84.2)	0.02
Statin or other lipid-lowering medication	7111 (94.7)	633 (90.8)	<0.0001
Diuretic	1869 (24.9)	341 (48.9)	<0.0001
Antidepressant	558 (7.5)	66 (9.5)	0.05
<b>Details of index event</b>			
Type of index MI			<0.001
STEMI	3845 (50.8)	304 (43.3)	
NSTEMI	3236 (42.7)	367 (52.3)	
Unknown	494 (6.5)	31 (4.4)	
Management of index MI			<0.001
PCI	6162 (81.3)	454 (64.7)	
CABG	564 (7.4)	94 (13.4)	
Medical	849 (11.2)	154 (21.9)	

Continuous variables presented as mean (%).

Medication data available for n = 7,525 patients without history of AF and n = 702 patients with a history of AF.

ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; ED, emergency department; GP, general practitioner; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST elevation myocardial infarction.

**Supplemental Table S3.** CHA<sub>2</sub>DS<sub>2</sub>-VASc scores and oral anticoagulant therapy at the time of enrolment in patients with a history of atrial fibrillation

CHA <sub>2</sub> DS <sub>2</sub> -VASc score	Total (N=702)	OAC at enrolment N (%)
1	16	6 (37.5)
2	64	23 (35.9)
3	162	78 (48.2)
4	177	79 (44.6)
5	140	79 (56.4)
≥6	143	83 (58.0)

OAC, oral anticoagulant.

**Supplemental Table S4.** Type of oral anticoagulant in 583 patients taking an oral anticoagulant at baseline

	<b>No history of AF (N=233)</b>	<b>History of AF (N=348)</b>	<b>Total (N=581)</b>
Warfarin	173 (74.3)	203 (58.3)	376 (64.7)
Other oral anticoagulant	60 (25.7)	145 (41.7)	205 (35.3)

Data presented as n (%)  
AF, atrial fibrillation

**Supplemental Table S5.** EQ-5D quality-of-life assessment in patients without a history of atrial fibrillation at enrolment, stratified by incident atrial fibrillation after enrolment

Variable	No incident AF (N=7534)	Incident AF (N=700)	<i>p</i> value
<b>Demographics &amp; clinical variables</b>			
EQ-5D UK-weighted index score			<0.0001
1	3559 (47.2)	241 (34.3)	
0.75–0.99	1996 (26.5)	201 (28.7)	
0.60–0.74	1394 (18.5)	167 (23.9)	
<0.60	585 (7.8)	91 (13.0)	
EQ-5D overall score			<0.0001
0	3489 (47.9)	70 (28.8)	
1	1619 (22.2)	51 (21.0)	
2	970 (13.3)	48 (19.8)	
3	563 (7.7)	32 (13.2)	
≥4	650 (8.9)	42 (17.3)	
EQ-5D mobility			<0.0001
No problems	5505 (75.5)	151 (62.1)	
Some problems	1776 (24.4)	92 (37.9)	
Severe problems	12 (0.2)	0 (0.0)	
EQ-5D self-care			0.12
No problems	6884 (94.4)	223 (91.8)	
Some problems	378 (5.2)	19 (7.8)	
Severe problems	31 (0.4)	1 (0.4)	
EQ-5D usual activities			<0.0001
No problems	5997 (82.2)	164 (67.5)	
Some problems	1217 (16.7)	75 (30.9)	
Severe problems	78 (1.1)	4 (1.6)	
EQ-5D pain			<0.0001
No problems	4682 (64.2)	106 (43.6)	
Some problems	2416 (33.1)	125 (51.4)	
Severe problems	195 (2.7)	12 (4.9)	
EQ-5D depression/anxiety			<0.0001
No problems	5559 (76.2)	154 (63.4)	
Some problems	1597 (21.9)	82 (33.7)	
Severe problems	136 (1.9)	7 (2.9)	
EQ-5D visual analogue scale score (0–100)			<0.0001
90–100	2071 (28.5)	53 (21.9)	
80–89	2081 (28.6)	49 (20.2)	
70–79	1544 (21.2)	58 (24.0)	
60–69	712 (9.8)	28 (11.6)	
<60	867 (11.9)	54 (22.3)	

N=47 patients with missing baseline EQ-5D data

AF, atrial fibrillation; EQ-5D, EuroQol five dimensions questionnaire.

**Supplemental table S6.** Kaplan-Meier risk (%) for clinical outcomes over 2-year follow-up by atrial fibrillation history

	No history of AF N=7575	History of AF N=702	<i>p</i> value
All-cause mortality	230 (3.1)	45 (6.5)	<0.001
MI	167 (2.3)	16 (2.4)	0.84
Stroke	35 (0.5)	8 (1.2)	0.01
Unstable angina with urgent revascularisation	85 (1.2)	6 (0.9)	0.55
CV mortality	126 (1.7)	37 (5.4)	<0.001
Bleeding requiring hospitalisation	81 (1.1)	19 (2.9)	<0.001
Primary composite	494 (6.6)	72 (10.5)	<0.001
Secondary composite	321 (4.3)	60 (8.8)	<0.001

Primary composite = all-cause mortality, myocardial infarction, stroke, unstable angina with urgent revascularisation.

Secondary composite = cardiovascular mortality, myocardial infarction, stroke.

Data presented as number of events (2-year Kaplan-Meier risk % estimate).

AF, atrial fibrillation; CV, cardiovascular; MI, myocardial infarction.